IFNG and melanoma: This remarkable pro-tumorigenic activity of IFN-γ in human melanoma was also observed in an earlier Phase III clinical trial, which showed that adjuvant treatment with daily subcutaneous injection of IFN-γ failed to improve disease-free survival or overall survival of patients with high-risk melanoma resected with curative intent, constituting strong evidence against any clinically beneficial application32.